Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Objectives:
1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic
colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV), 5-Fluorouracil
(5-FU), irinotecan) plus bevacizumab as first line treatment.
2. To determine the objective response rate and the duration of objective response in this
population.
3. To assess overall survival (OS) in this population.
4. To measure the effect of treatment on intratumoral blood volume and microvascular
permeability by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in
consenting patients in whom it is technically feasible.
5. To correlate plasma proteomics with response.
6. To assess the safety of this regimen.